Qrons (QRON) 10-Q 6 Nov 18 2018 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Sep. 30, 2018	Nov. 14, 2018
Document and Entity Information [Abstract]
Entity Registrant Name	Qrons Inc.
Entity Central Index Key	1,689,084
Trading Symbol	QRON
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Type	10-Q
Document Period End Date	Sep. 30, 2018
Document Fiscal Year Focus	2,018
Document Fiscal Period Focus	Q3
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding		12,849,581

Condensed Balance Sheets (Unaud

Condensed Balance Sheets (Unaudited) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Current assets
Cash and cash equivalents	$ 198,622	$ 57,767
Prepaid expenses	54,991	15,812
Total current assets	253,613	73,579
TOTAL ASSETS	253,613	73,579
Current liabilities
Accounts payable and accrued liabilities	14,267	14,141
Accounts payable and accrued liabilities - related party	2,915	1,410
Convertible note - related party, net of debt discount	25,000	6,665
Derivative liabilities	30,506	31,090
Total current liabilities	72,688	53,306
Total liabilities	72,688	53,306
Stockholders' equity
Series A Preferred Shares: $0.001 par value, authorized 10,000; 2,000 shares issued and outstanding	2	2
Common stock, $0.0001 par value: shares authorized 100,000,000; 12,826,853 and 12,404,910 shares issued and outstanding at September 30, 2018 and December 31, 2017, respectively	1,283	1,240
Additional Paid-in Capital	3,497,774	1,611,711
Accumulated deficit	(3,318,134)	(1,592,680)
Total stockholder's equity	180,925	20,273
TOTAL LIABILITIES & STOCKHOLDERS' EQUITY	$ 253,613	$ 73,579

Condensed Balance Sheets (Una_2

Condensed Balance Sheets (Unaudited) (Parenthetical) - $ / shares	Sep. 30, 2018	Dec. 31, 2017
Statement of Financial Position [Abstract]
Series A Preferred Shares, par value	$ 0.001	$ 0.001
Series A Preferred Shares, authorized	10,000	10,000
Series A Preferred Shares, shares issued	2,000	2,000
Series A Preferred Shares, shares outstanding	2,000	2,000
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	12,826,853	12,404,910
Common stock, shares outstanding	12,826,853	12,404,910

Condensed Statements of Operati

Condensed Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Income Statement [Abstract]
Net sales
Operating expenses:
Research and development expenses	104,798	8,406	237,770	10,120
Professional fees	6,300	8,170	35,449	11,297
General and administrative expenses	423,216	31,643	1,432,980	47,252
Total operating expenses	534,314	48,219	1,706,199	68,669
Income (loss) from operations	(534,314)	(48,219)	(1,706,199)	(68,669)
Other income (expense)
Interest expense	(6,048)	(1,785)	(19,839)	(7,215)
Change in derivative liabilities	(2,979)	(47,954)	584	(47,954)
Total Other income (expense)	(9,027)	(49,739)	(19,255)	(55,169)
Net (loss)	$ (543,341)	$ (97,958)	$ (1,725,454)	$ (123,838)
Net (loss) per common shares (basic and diluted)	$ (0.04)	$ 0	$ (0.14)	$ 0
Weighted average shares outstanding Basic and diluted	12,807,584	11,552,000	12,744,561	11,544,293

Condensed Statements of Cash Fl

Condensed Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Cash Flows From Operating Activities
Net loss	$ (1,725,454)	$ (123,838)
Adjustments to reconcile net loss to net cash provided from (used by) operating activities:
Stock awards recorded as advisory services	178,000
Stock options granted and recorded as administrative expenses and advisory services	1,183,106
Accretion of debt discount	18,335	6,599
Change in derivative liabilities	(584)	47,954
Changes in operating assets and liabilities:
Prepaid expenses	(39,179)
Accounts payable and accrued liabilities	126	6,059
Accounts payable and accrued liabilities, related party	1,505
Net cash provided (used by) operating activities	(384,145)	(63,226)
Cash Flows From Investing Activities
Net cash provided from (used by) investing activities
Cash Flows From Financing Activities
Proceeds from convertible note		15,000
Proceeds from private placement	525,000	32,000
Financing costs		(22,548)
Net cash provided from financing activities	525,000	24,452
Increase (decrease) in cash and cash equivalents	140,855	(38,774)
Cash at beginning of period	57,767	155,242
Cash at end of period	198,622	116,468
SUPPLEMENTAL DISCLOSURES
Interest paid
Income taxes paid

Description of Business and Bas

Description of Business and Basis of Presentation	9 Months Ended
	Sep. 30, 2018
Description of Business and Basis of Presentation [Abstract]
Description of Business and Basis of Presentation	Note 1 – Description of Business and Basis of Presentation Organization and nature of business: Qrons Inc. ("Qrons" or the "Company") was incorporated under the laws of the State of Wyoming on August 22, 2016 under the name BioLabMart Inc. On July 6, 2017, the board of directors and a majority of the Company's shareholders approved an amendment to the Company's Articles of Incorporation to change the name of the Company from "BioLabMart Inc." to "Qrons Inc.". On August 8, 2017, the Company filed Amended Articles of Incorporation with the State of Wyoming to effectuate such name change. The Company's common stock was approved by the Financial Industry Regulatory Authority ("FINRA") for quotation on the OTC pink sheets under the symbol "BLMB" as of July 3, 2017. FINRA announced the Company's name change to Qrons Inc. on its Daily List on August 9, 2017. The new name and symbol change to "QRON" for the OTC Market was effective August 10, 2017. The Company is a p reclinical stage biotechnology company developing advanced cell-based solutions to combat neuronal injuries and achieve a breakthrough in the treatment of traumatic brain injuries ("TBIs"), an unmet medical need. We believe that our approach is The Company collaborates treatment that integrates proprietary, engineered mesenchymal stem cells, 3D printable implant, smart materials and a novel delivery system. Our headquarters are located at 777 Brickell Avenue, Suite 500, Miami, Florida 33131. Ariel Agreements On December 14, 2016, the Company entered into a license and research funding agreement ("License Agreement") with Ariel Scientific Innovations Ltd., formerly known as Ariel University R&D Co., Ltd., ("Ariel"), a wholly owned subsidiary of Ariel University, based in Ariel, Israel. Under the terms of the License Agreement, Professor Danny Baranes, the principal investigator and his research team will carry out further research relating to cell treatment with conditioned medium for neuronal tissue regeneration and repair. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty- bearing license in Ariel patents and know-how to develop and commercialize products based on or incorporating conditioned medium for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding (the "Products). Under the License Agreement, the Company is required to use its best efforts to develop and commercialize the Products in accordance with development milestones set forth in the Agreement. In lieu of extending the research financing and research period under the License Agreement beyond the initial 12 months, on December 14, 2017, the Company entered into a 12-month services agreement with Ariel (the "Services Agreement") pursuant to which a team at Ariel under the direction of Prof. Danny Baranes will conduct molecular biology research activities involving the testing of implant materials for the Company. On April 12, 2018, the Services Agreement was amended to provide for additional services as the Company may request. On March 6, 2018, the Company entered into an additional services agreement with Ariel for the services of Professor Gadi Turgeman and his neurobiology research team in their lab. Dartmouth Agreements On October 17, 2017, the Company entered into an Option Agreement (the "Agreement") with the Trustees of Dartmouth College which provides for, among other things, the grant to the Company of a one-year exclusive option to negotiate a worldwide, royalty bearing, exclusive license with Dartmouth for 3D printable materials in the field of human and animal health. During the option period, the Company agreed to use all commercially reasonable resources to evaluate the intellectual property and provide quarterly milestone reports and a commercialization plan upon exercise of the option. Pursuant to the Agreement, the Company agreed to finance the prosecution of patents by Dartmouth to protect its intellectual property. Further, the Agreement provides for the payment by the Company of an option fee and certain license fees and royalty payments based upon the Company's product sales, as part of a final negotiated license agreement. The Company exercised its option on March 26, 2018 to negotiate definitive license terms, as it continues further evaluation and research. On July 12, 2018, the Company entered into a one-year sponsored research agreement (the "Sponsored Research Agreement"), with the Trustees of Dartmouth College ("Dartmouth") pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement. Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned. Dartmouth shall retain an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Agreement on a non-exclusive royalty-free basis for research and education purposes. The Agreement may be terminated earlier than one year upon written agreement of the parties, a material breach which is not cured within 30 days of notice thereof, if Professor Ke no longer conducts the research under the Agreement and a successor acceptable to both parties is not available, or in the event of an unauthorized assignment of the Company's rights and obligations under the Agreement.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Sep. 30, 2018
Summary of Significant Accounting Policies [Abstract]
Summary of Significant Accounting Policies	Note 2 – Summary of Significant Accounting Policies Financial Statement Presentation: The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission(the "SEC"), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP"), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017. In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three and nine-month periods have been made. Results for the interim period presented are not necessarily indicative of the results that might be expected for the entire fiscal year. Fiscal year end: Use of Estimates: Cash Equivalents: Research and Development Costs: Advertising and Marketing Costs: The Company incurred $48,832 and $15,657 in advertising or marketing costs during the nine months ended September 30, 2018 and 2017, respectively. Related parties: Stock-Based Compensation and Other Share-Based Payments: Stock Plan Fair Value of Financial Instruments FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. FASB ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. FASB ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 Level 2 Level 3 If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument. The following table provides a summary of the fair value of our derivative liabilities as of September 30, 2018 and December 31, 2017: Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of September 30, 2018: Liabilities Derivative liabilities $ - $ - $ 30,506 As of December 31, 2017: Liabilities Derivative liabilities $ - $ - $ 31,090 Warrants: "Derivatives and Hedging – Contracts in Entity's Own Equity" Income taxes: Basic and Diluted Loss Per Share Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The computation of basic loss per share for the nine-month period ended September 30, 2018 and 2017 excludes potentially dilutive securities of underlying share purchase warrants, convertible notes, stock options and preferred shares, because their inclusion would be antidilutive. As a result, the computations of net loss per share for each period presented is the same for both basic and fully diluted. The table below reflects the potentially dilutive securities at each reporting period which have been excluded from the computation of diluted net loss per share: September 30, 2018 September 30, 2017 Stock purchase warrants 52,000 566,000 Research Warrants at 3% of issued and outstanding shares 384,806 - Convertible Notes 28,778 32,178 Series A Preferred shares 700 700 Stock options vested 30,000 - Stock options not yet vested 690,000 - Stock awards not yet vested 290,000 - 1,476,284 598,878 New Accounting Pronouncements:

Going Concern

Going Concern	9 Months Ended
	Sep. 30, 2018
Going Concern [Abstract]
Going Concern	Note 3 – Going Concern The Company has experienced net losses to date, and it has not generated revenue from operations. While the Company has recently raised proceeds, it does not believe its resources will be sufficient to meet its operating and capital needs beyond the fourth quarter of 2018. The Company expects it will require additional capital to fully implement the scope of its proposed business operations, which raises substantial doubt about its ability to continue as a going concern. The Company will have to continue to rely on equity and debt financing. There can be no assurance that financing, whether debt or equity, will always be available to the Company in the amount required at any particular time or for any particular period or, if available, that it can be obtained on favorable terms. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts, or amount and classification of liabilities that might cause results from this uncertainty.

Convertible Note - Related Part

Convertible Note - Related Party and Derivative Liabilities	9 Months Ended
	Sep. 30, 2018
Convertible Note - Related Party and Derivative Liabilities [Abstract]
Convertible Note - Related Party and Derivative Liabilities	Note 4 – Convertible Note – Related Party and Derivative Liabilities On September 1, 2016, the Company entered into a convertible debenture agreement with CubeSquare, LLC ("CubeSquare"), of which our Chief Executive Officer is the managing partner and our President is a 25% owner. The Company received proceeds of $10,000 during fiscal 2016 ("Note 1"). The note bears interest at 8% per annum and was due on September 1, 2017. Interest accrues from September 1, 2016 and is payable on maturity. Interest is payable, at the lender's option, in cash or common stock. Any portion of the loan and unpaid interest are convertible at any time at the option of the lender into shares of common stock of the Company at a conversion price of the greater of (i) $0.0625 per share if the Company's shares are not trading on a public market and; (ii) in the event the Company's shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender. On September 28, 2017 the Company and CubeSquare amended Note 1 to extend the maturity date from September 1, 2017 to September 1, 2018 and on September 9, 2018, the Company further amended Note 1 to extend the maturity date to September 1, 2019, under the same terms and conditions. On September 27, 2017, the Company entered into a second convertible debenture agreement with CubeSquare under which the Company received proceeds of $15,000 (Note 2). Note 2 bears interest at 8% per annum and is due on September 27, 2018. Interest shall accrue from September 27, 2017 and shall be payable on maturity. Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare. On September 9, 2018, Note 2 was amended to extend the maturity date until September 27, 2019. The Company analyzed the amendment to Note 1 and Note 2 under and concluded that these two convertible debentures We estimated the fair value of the derivative on the inception dates, and subsequently, using the Black-Scholes valuation technique, adjusted for the effect of dilution, because that technique embodies all of the assumptions (including, volatility, expected terms, and risk-free rates) that are necessary to fair value complex derivate instruments. The carrying value of these convertible notes is as follows: September 30, 2018 December 31, 2017 Face value of certain convertible notes $ 25,000 $ 25,000 Less: unamortized discount - (18,335 ) Carrying value $ 25,000 $ 6,665 Amortization of the discount over the three months ended September 30, 2018 and 2017 totaled $5,541 and $1,571, respectively, which amounts have been recorded as interest expense. Amortization of the discount over the nine months ended September 30, 2018 and 2017 totaled $18,335 and $6,599, respectively, which amounts have been recorded as interest expense. As a result of the application of ASC No. 815 in the periods ended September 30, 2018 and December 31, 2017 the fair value of the conversion feature is summarized as follows: Balance at December 31, 2017 $ 31,090 Derivative addition associated with convertible notes - Change in fair value (584 ) Balance at September 30, 2018 $ 30,506 The fair value at the commitment and re-measurement dates for the Company's derivative liabilities were based upon the following management assumptions as of September 30, 2018 and commitment date: Commitment Date September 30, 2018 December 31, 2017 Expected dividends 0 0 0 Expected volatility 101% ~103% 77% ~ 83% 110% ~ 115% Expected term 0.92 ~ 1 year 0.92 ~0.99 year 0.67 ~0.74 year Risk free interest rate 1.33% 2.59% 1.53% ~ 1.65%

License and Research Funding Ag

License and Research Funding Agreements	9 Months Ended
	Sep. 30, 2018
License And Research Funding Agreements [Abstract]
License and Research Funding Agreements	Note 5 – License and Research Funding Agreements On December 14, 2016, the Company entered into the License Agreement with Ariel. Under the terms of the License Agreement, Professor Danny Baranes, the principal investigator and his research team will carry out further research relating to cell treatment with conditioned medium for neuronal tissue regeneration and repair. The Company shall fund the research completed during the research period in the total amount of $100,000. In consideration for payments under the License Agreement, the Company received an exclusive worldwide royalty- bearing license in Ariel patents and know-how to develop and commercialize products based on or incorporating conditioned medium for neuronal tissue regeneration and/or repair, resulting from Ariel's research or technology or the Company's research funding (the "Products). Under the License Agreement, the Company is required to use its best efforts to develop and commercialize the Products in accordance with development milestones set forth in the Agreement. In addition, upon the occurrence of an Exit Event (as defined in the License Agreement) of the Company or of any affiliate commercializing the products, the Company is obligated to issue to Ariel an immediately exercisable warrant for that number of shares equal to 4% of the issued and outstanding shares of the Company at the time of issuance. The Company and Ariel entered into Addendum #1, effective December 13, 2017 (the "Addendum") to the License Agreement pursuant to which Ariel was permitted to exercise a portion of the warrant granted pursuant to the License Agreement. On December 13, 2017, the Company issued 119,950 shares of common stock to Ariel, representing 1% of the issued and outstanding shares of the Company on such date, and valued at $335,860. The right to the balance of the shares subject to the warrant remains subject to the terms of the License Agreement and the occurrence of an Exit Event (as described in the License Agreement). In addition, the Addendum provides that Ariel may not request a demand registration until the balance of the shares subject to the warrant is exercised. In addition to the other payments, the Company will pay Ariel upon the occurrence of the following milestone events, additional payments which shall be due within 6 months of completion of the milestone: - Upon successful clinical FDA Phase II completion - $130,000; and - Upon successful clinical FDA Phase III completion - $390,000 Upon successful development and commercialization and in recognition of the rights and licenses granted to the Company pursuant to the License Agreement, the Company will be subject to certain royalty payments as specified in the License Agreement. During the year ended December 31, 2017, the Company incurred total research and development costs of $1,179,777, which amount includes the aforementioned value of 119,950 shares of common stock at In lieu of extending the research financing and research period under the License Agreement with Ariel beyond the initial 12 months, on December 14, 2017, the Company entered into a 12-month services agreement with Ariel (the "Services Agreement") pursuant to which a team at Ariel University under the direction of Professor Danny Baranes will conduct molecular biology research activities involving the testing of scaffold materials for the Company. As compensation for such services, the Company paid Ariel (i) $17,250 on December 19, 2017 and an additional $17,250 on April 26, 2018. On April 12, 2018, the Services Agreement was amended to provide for the payment by the Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request. On March 6, 2018, the Company entered into an additional service agreement with Ariel for the services of Professor Gadi Turgeman and his stem cells research team in their lab pursuant to which the Company paid Ariel $20,580 on each of March 19, 2018 and August 22, 2018. On July 12, 2018, the Company entered into the Sponsored Research Agreement with Dartmouth pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement. Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned. Dartmouth shall retain an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Agreement on a non-exclusive royalty-free basis for research and education purposes. The Agreement may be terminated earlier than one year upon written agreement of the parties, a material breach which is not cured within 30 days of notice thereof, if Professor Ke no longer conducts the research under the Agreement and a successor acceptable to both parties is not available, or in the event of an unauthorized assignment of the Company's rights and obligations under the Agreement.

Commitments

Commitments	9 Months Ended
	Sep. 30, 2018
Commitments [Abstract]
Commitments	Note 6 – Commitments (1) Service Agreement with Ariel - Prof. Danny Baranes On December 14, 2017, the Company entered into a 12-month services agreement pursuant to which a team at Ariel under the direction of Prof. Danny Baranes will conduct molecular biology research activities involving the testing of implant materials for the Company. As compensation for the services provided, the Company will pay Ariel (i) $17,250 within five business days of the execution of the Services Agreement, and (ii) $17,250 by May 1, 2018. The Services Agreement may be terminated by the non-breaching party upon a material breach that is not cured within 30 days or by the Company upon thirty days' prior written notice to Ariel. Ariel must keep confidential information of the Company confidential for five years after the term of the Services Agreement. During the year ended December 31, 2017, $17,250 was paid and on April 26, 2018, the remaining installment of $17,250 was paid. During the year ended December 31, 2017, $1,438 was expensed, and during the nine months ended September 30, 2018 $25,875 was expensed, and the remaining $7,187, which amount is reflected on the Company's balance sheets as prepaid expenses, will be expensed in a subsequent period. On April 12, 2018, the Services Agreement was amended to provide for the payment by the Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request. During the nine-month period ended September 30, 2018, the Company paid $14,082 for these additional fees. (2) Service Agreement with Ariel - Dr. Gadi Turgeman On March 6, 2018, the Company entered into a service agreement for the services of Professor Gadi Turgeman and his stem cells research team in their lab. The Services Agreement may be terminated by the non-breaching party upon a material breach that is not cured within 30 days or by the Company upon thirty days' prior written notice to Ariel. Ariel must keep confidential information of the Company confidential for six years after the term of the Services Agreement. (3) Science Advisory Board Member Consulting Agreements (the "Agreements") As part of its ongoing program of research and development, the Company has retained distinguished scientists and other qualified individuals to advise the Company with respect to its technology and business strategy and to assist it in the research, development and analysis of the Company's technology and products. In furtherance thereof, the Company has retained certain Advisors as members of its Scientific Advisory Board as described below, and the Company and Advisors have entered into agreements with the following terms and conditions: - Scientific Advisory Board and Consulting Services - Advisor shall provide general consulting services to Company (the "Services") as a member of its Scientific Advisory Board ("SAB"). As a member of the SAB, Advisor agrees to provide the Services as follows: (a) attending meetings of the Company's SAB; (b) performing the duties of a SAB member at such meetings, as established from time to time by the mutual agreement of the Company and the SAB members, including without limitation meeting with Company employees, consultants and other SAB members, reviewing goals of the Company and assisting in developing strategies for achieving such goals, and providing advice, support, theories, techniques and improvements in the Company's scientific research and product development activities; and (c) providing consulting services to Company at its request, including a reasonable amount of informal consultation over the telephone or otherwise as requested by Company. Advisor's consultation with Company will involve services as scientific, technical and business advisor to the Company and its senior team as needed with respect to the field of neuronal injuries and neuro degenerative diseases ("the "Field") and requires the application of unique, special and extraordinary skills and knowledge that Advisor possesses in the Field. - SAB Consulting Compensation - the Company shall grant to Advisor the option to purchase certain number of shares of the common stock of the Company as per the stock option award grant. The options are subject to terms and provisions of the Company's 2016 Stock Option and Stock Award Plan. On April 16, 2018, the Company entered into a one-year advisory board member consulting agreement with an assistant Professor of Chemistry at Dartmouth College to serve on the Company's Scientific Advisory Board. In consideration for serving on the Scientific Advisory Board, the Company granted an option to purchase 30,000 shares of its common stock under certain vesting terms to the assistant Professor. On August 15, 2018, the Company entered into an Agreement with an Advisor under the terms of which the Company granted an option to purchase 20,000 shares of common stock under the 2016 Stock Option and Award Plan subject to certain vesting terms. (4) Business Advisory Board Agreement On January 23, 2018, the Company entered into a one-year advisory board member consulting agreement with Pavel Hilman, the controlling shareholder of Conventus Holdings SA, a BVI corporation ("Conventus"), under which Mr. Hilman will serve on the Company's Advisory Board as a business advisor. The Advisory Board Agreement will automatically renew for up to two additional one-year periods, unless earlier terminated by either party upon 30 days' prior written notice to the other party. In consideration for serving on the Advisory Board, the Company awarded 10,000 shares of its common stock to Mr. Hilman under its 2016 Stock Option and Stock Award Plan. Investor Relations Agreement On April 23, 2018, the Company entered into a six-month investor relations agreement with an investor relations firm for a monthly consulting fee of $5,000 and the issuance of 75,000 shares of common stock payable on signing the agreement. On June 23, 2018, the Company gave notice of rescission of the agreement to such firm and requested the return of the consulting fee paid and the 75,000 shares of common stock. As a result, the Company has not recorded any fees for services rendered past June 23, 2018. A total of $10,000 representing April 2018 and May 2018 monthly consulting fees is reflected in the statement of operations and a total of $150,000, the fair market value of the issued shares, was expensed on issue. (6) Sponsored Research Agreement The Agreement may be terminated earlier than one year upon written agreement of the parties, a material breach which is not cured within 30 days of notice thereof, if Professor Ke no longer conducts the research under the Agreement and a successor acceptable to both parties is not available, or in the event of an unauthorized assignment of the Company's rights and obligations under the Agreement. During the nine months ended September 30, 2018, $36,293 was paid and recorded as prepaid expenses, of which $9,073 was expensed in the nine-month period ended September 30, 2018, and the remaining $27,220 will be expensed in a subsequent period.

Stock Plan

Stock Plan	9 Months Ended
	Sep. 30, 2018
Stock Plan [Abstract]
Stock Plan	Note 7 – Stock Plan 2016 Stock Option and Stock Award On December 14, 2016, the Board adopted the Company's 2016 Stock Option and Stock Award Plan (the "Plan"). The Plan provides for the award of stock options (incentive and non-qualified), stock awards and stock appreciation rights to officers, directors, employees and consultants who provide services to the Company. The terms of awards under the Plan are made by the Administrator of the Plan appointed by the Company's Board of Directors (the "Board"), or in the absence of an Administrator, by the Board. The Company has reserved 10 million shares for issuance under the Plan. Stock Awards: On December 14, 2016, the Board awarded to each of its Science Advisors, Prof. Danny Baranes and Dr. Liat Hammer, a total of 440,000 shares of common stock of which 150,000 shares vested on December 14, 2016, 145,000 shares vested on December 14, 2017, and 145,000 shares will vest on December 14, 2018, provided such advisors are still providing services to the Company. The value of the vested awards had been recorded as research and development expenses in the respective periods. A total of 290,000 stock awards are expected to vest during the fourth quarter of fiscal 2018. On January 23, 2018, the Company awarded 10,000 shares of its common stock to Mr. Hilman under its 2016 Stock Option and Stock Award Plan, which shares were fully vested and recorded as advisory services on issuance. For the nine months ended September 30, 2018 For the year ended December 31, 2017 Number of shares vested in period 10,000 290,000 Fair market value per share $ 2.80 $ 2.80 Stock based compensation recognized $ 28,000 $ 812,000 Stock Options: (a) Stock Options granted to Science Advisors: On November 15, 2017, under the 2016 Stock Option and Award Plan, the Board awarded two of its Science Advisors the following three-year stock options: (i) an immediately exercisable option to purchase 6,667 shares of common stock at an exercise price of $2.00 per share, (ii) an option to purchase 6,667 shares of common stock exercisable on November 15, 2018 at an exercise price of $2.00 per share and (iii) an option to purchase 6,666 shares of common stock exercisable on November 15, 2019 at an exercise price of $2.00 per share, provided the advisors are still providing services to the Company. On November 15, 2017, under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 15,000 shares of common stock, exercisable on November 15, 2018 at an exercise price of $0.40 per share and (ii) an option to purchase 15,000 shares of common stock exercisable on November 15, 2019 at an exercise price of $0.40 per share, provided the advisor is still providing services to the Company. On April 16, 2018 , under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 10,000 shares of common stock, exercisable on April 16, 2018 at an exercise price of $2.00 per share and (ii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company. provided the advisor is still providing services to the Company. On August 15, 2018, under the 2016 Stock Option and Award Plan, the Board granted a Science Advisor an option to purchase an aggregate of 20,000 shares of common stock at an exercise price of $2.00 per share. The option vests as to 6,667 shares on each of August 15, 2018 and August 15, 2019 and as to 6,666 shares on August 15, 2020 and remains exercisable as to each such installment for three years from the date of vesting. During the year ended December 31, 2017, total recognized compensation in respect of the above stock option compensation was $29,000, which amount has been allocated as advisory services as part of general and administrative expenses. The Company recorded stock-based compensation in the amount of $48,078 and $122,816 in respect to these options grants during the three and nine months ended September 30, 2018, respectively, which amounts have been allocated as advisory services as part of general and administrative expenses. As of September 30, 2018, total unrecognized compensation remaining to be recognized in future periods totaled $92,671. (b) Stock Options granted to Officers: On December 4, 2017, the Board granted five-year options to each of its two officers . The options have an exercise price of $2.00 and vest and become exercisable on December 4, 2018. During the year ended December 31, 2017, total recognized compensation of $106,029 was recorded as general and administrative expenses. During the three and nine months ended September 30, 2018, total recognized compensation of $353,430 and $1,060,290, respectively, was recorded as general and administrative expenses. As of September 30, 2018, total unrecognized compensation remaining to be recognized in future periods totaled $246,755. using the Black-Scholes option-pricing model with the following assumptions at the measurement date(s): Measurement date Dividend yield 0% Expected volatility 114.69 ~ 126.34% Risk-free interest rate 1.79% ~ 2.68% Expected life (years) 3 ~ 5 Stock Price $ 2.00 ~ 2.80 Exercise Price $ 0.40 ~ 2.00 A summary of the activity for the Company's stock options for the nine-month period ended September 30, 2018 and for the year ended December 31, 2017, is as follows: September 30, 2018 December 31, 2017 Weighted Average Weighted Average Shares Exercise Price Shares Exercise Price Outstanding, beginning of period 670,000 $ 1.93 - $ - Granted 50,000 $ 2.00 670,000 $ 1.93 Exercised - $ - - $ - Canceled - $ - - $ - Outstanding, end of period 720,000 $ 1.93 670,000 $ 1.93 Options exercisable, end of period 30,000 $ 2.00 13,334 $ 2.00 Options expected to vest, end of period 690,000 $ 1.93 656,666 $ 1.89 Weighted average fair value of options granted $ 2.30 $ 2.36

Capital Stock

Capital Stock	9 Months Ended
	Sep. 30, 2018
Capital Stock [Abstract]
Capital Stock	Note 8 – Capital Stock Authorized: The Company has authorized 100,000,000 shares of common stock, par value $0.0001 and 10,000 shares of preferred stock which is designated as Series A Preferred Stock, par value $0.001. Series A Preferred Stock: The Series A Preferred Stock is redeemable at the option of the Company at any time, in whole or in part, upon 10 trading days prior notice, at a price of $1.00 per share plus 4% per annum from the date of issuance (the "Stated Value"). The holders of the Series A Preferred Stock are entitled to a liquidation preference equal to the Stated Value, prior to the holders of other preferred stock or common stock. The holders of the Series A Preferred Stock have the right to convert such stock into common stock at a conversion rate equal to the Stated Value as of the conversion date divided by the average closing price of the common stock for the five previous trading days. The Company is required to reserve sufficient number of shares for the conversion of the Series A Preferred Stock. The holders of Class A Preferred Stock shall vote together as a single class with the holders of the Company's common stock and the holders of any other class or series of shares entitled to vote with the common stock, with the holders of Class A Preferred Stock being entitled to 66 2/3% of the total votes on There was a total of 2,000 shares of Series A Preferred Stock issued and outstanding as at September 30, 2018 and December 31, 2017. Common Stock issuances during the nine months ended September 30, 2018: On January 23, 2018 the Company sold 312,500 shares of its common stock to Conventus and raised $500,000 pursuant to a subscription agreement in a private placement offering. The proceeds of the offering will be used for research and general corporate purposes. On January 23, 2018, the Company issued 10,000 shares for advisory services (Note 6(4)). The shares were valued at fair market value on the date of issuance for a total of $28,000 or $2.80 per share. On February 6, 2018, the Company shares of common stock On April 23, 2018, the Company issued 75,000 shares of its common stock in respect of an investor relations services agreement which was rescinded on June 23, 2018 (Note 6(5)). The shares were valued at the fair market value on the date of issuance for a total of $150,000, or $2.00 per share. On September 16, 2018 the Company sold 22,728 shares of its common stock to an investor and raised $25,000 pursuant to a subscription agreement in a private placement offering. The proceeds of the offering will be used for research and general corporate purposes. Common Stock issuances as of December 31, 2017: On December 13, 2017, 119,950 shares were issued to Ariel as an exercise of warrants pursuant to a License Agreement (Note 5 – License and Research Funding Agreement). These shares were valued at $335,860 or $2.80 per share, based on fair market value, and the associated cost was recorded as research and development expenses. On December 14, 2017, the Company issued 290,000 shares to two Scientific Advisors as a stock award, During the year ended December 31, 2017, the Company received aggregate proceeds of $32,000 in private placement subscriptions for a total of 128,000 shares. During the year ended December 31, 2017 the Company shares of common stock Share Purchase Warrants In accordance with authoritative accounting guidance, the fair value of the aforementioned warrants was calculated using the Black-Scholes option-pricing model with the following assumptions at the measurement date(s): Measurement date Dividend yield 0% Expected volatility 97.90~119.33% Risk-free interest rate 1.47~1.60% Expected life (years) 2.71~2.92 Stock Price $ 0.25 Exercise Price $ 0.40 As of September 30, 2018, and December 31, 2017, the following common stock purchase warrants were outstanding: Warrants (1) Weighted Average Exercise Price Outstanding – December 31, 2016 502,000 $ 0.40 Granted 64,000 0.40 Forfeited/Canceled - - Exercised 512,000 (2) 0.40 Outstanding – December 31, 2017 54,000 0.40 Granted - - Forfeited/Canceled - - Exercised 2,000 (3) 0.40 Outstanding – September 30, 2018 52,000 $ 0.40 (1) Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40. (2) During the year ended December 31, 2017, investors exercised 512,000 share purchase warrants and received 442,960 underlying shares for exercise on a cashless basis. (3) During the nine-month period ended September 30, 2018, investors exercised 2,000 share purchase warrants and received 1,715 underlying shares for exercise on a cashless basis.

Subsequent Events

Subsequent Events	9 Months Ended
	Sep. 30, 2018
Subsequent Events [Abstract]
Subsequent Events	Note 9 – Subsequent Events On October 8, 2018 the Company sold 22,728 shares of its common stock to an investor and raised $25,000 pursuant to a subscription agreement in a private placement offering. The proceeds of the offering will be used for research and general corporate purposes. The Company has evaluated subsequent events from the balance sheet date through the date that the financial statements were issued and determined that there are no additional subsequent events to disclose.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Sep. 30, 2018
Summary of Significant Accounting Policies [Abstract]
Financial Statement Presentation	Financial Statement Presentation: The accompanying unaudited condensed financial statements of the Company have been prepared in accordance with the rules and regulations of the Securities and Exchange Commission(the "SEC"), including the instructions to Form 10-Q and Regulation S-X. Certain information and note disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States of America ("U.S. GAAP"), have been condensed or omitted from these statements pursuant to such rules and regulations and, accordingly, they do not include all the information and notes necessary for comprehensive financial statements and should be read in conjunction with our audited financial statements included in our Annual Report on Form 10-K for the year ended December 31, 2017. In the opinion of the management of the Company, all adjustments, which are of a normal recurring nature, necessary for a fair statement of the results for the three and nine-month periods have been made. Results for the interim period presented are not necessarily indicative of the results that might be expected for the entire fiscal year.
Fiscal year end	Fiscal year end:
Use of Estimates	Use of Estimates:
Cash Equivalents	Cash Equivalents:
Research and Development Costs	Research and Development Costs:
Advertising and Marketing Costs	Advertising and Marketing Costs: The Company incurred $48,832 and $15,657 in advertising or marketing costs during the nine months ended September 30, 2018 and 2017, respectively.
Related parties	Related parties:
Stock-Based Compensation and Other Share-Based Payments	Stock-Based Compensation and Other Share-Based Payments: Stock Plan
Fair Value of Financial Instruments	Fair Value of Financial Instruments FASB ASC 820, Fair Value Measurements and Disclosures, defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. FASB ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. FASB ASC 820 describes three levels of inputs that may be used to measure fair value: Level 1 Level 2 Level 3 If the inputs used to measure the financial assets and liabilities fall within more than one level described above, the categorization is based on the lowest level of input that is significant to the fair value measurement of the instrument. The following table provides a summary of the fair value of our derivative liabilities as of September 30, 2018 and December 31, 2017: Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of September 30, 2018: Liabilities Derivative liabilities $ - $ - $ 30,506 As of December 31, 2017: Liabilities Derivative liabilities $ - $ - $ 31,090
Warrants	Warrants: "Derivatives and Hedging – Contracts in Entity's Own Equity"
Income taxes	Income taxes:
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share Potential common stock consists of the incremental common stock issuable upon the exercise of common stock warrants (using the if-converted method), convertible notes, classes of shares with conversion features, and stock awards and stock options. The computation of basic loss per share for the nine-month period ended September 30, 2018 and 2017 excludes potentially dilutive securities of underlying share purchase warrants, convertible notes, stock options and preferred shares, because their inclusion would be antidilutive. As a result, the computations of net loss per share for each period presented is the same for both basic and fully diluted. The table below reflects the potentially dilutive securities at each reporting period which have been excluded from the computation of diluted net loss per share: September 30, 2018 September 30, 2017 Stock purchase warrants 52,000 566,000 Research Warrants at 3% of issued and outstanding shares 384,806 - Convertible Notes 28,778 32,178 Series A Preferred shares 700 700 Stock options vested 30,000 - Stock options not yet vested 690,000 - Stock awards not yet vested 290,000 - 1,476,284 598,878
New Accounting Pronouncements	New Accounting Pronouncements:

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Sep. 30, 2018
Summary of Significant Accounting Policies [Abstract]
Summary of the fair value of our derivative liabilities	Fair value measurements on a recurring basis Level 1 Level 2 Level 3 As of September 30, 2018: Liabilities Derivative liabilities $ - $ - $ 30,506 As of December 31, 2017: Liabilities Derivative liabilities $ - $ - $ 31,090
Schedule of potentially dilutive securities	September 30, 2018 September 30, 2017 Stock purchase warrants 52,000 566,000 Research Warrants at 3% of issued and outstanding shares 384,806 - Convertible Notes 28,778 32,178 Series A Preferred shares 700 700 Stock options vested 30,000 - Stock options not yet vested 690,000 - Stock awards not yet vested 290,000 - 1,476,284 598,878

Convertible Note - Related Pa_2

Convertible Note - Related Party and Derivative Liabilities (Tables)	9 Months Ended
	Sep. 30, 2018
Convertible Note - Related Party and Derivative Liabilities [Abstract]
Schedule of convertible notes	September 30, 2018 December 31, 2017 Face value of certain convertible notes $ 25,000 $ 25,000 Less: unamortized discount - (18,335 ) Carrying value $ 25,000 $ 6,665
Schedule of fair value of conversion feature	Balance at December 31, 2017 $ 31,090 Derivative addition associated with convertible notes - Change in fair value (584 ) Balance at September 30, 2018 $ 30,506
Schedule of fair value at commitment and re-measurement dates derivative liabilities	Commitment Date September 30, 2018 December 31, 2017 Expected dividends 0 0 0 Expected volatility 101% ~103% 77% ~ 83% 110% ~ 115% Expected term 0.92 ~ 1 year 0.92 ~0.99 year 0.67 ~0.74 year Risk free interest rate 1.33% 2.59% 1.53% ~ 1.65%

Stock Plan (Tables)

Stock Plan (Tables)	9 Months Ended
	Sep. 30, 2018
Stock Plan [Abstract]
Schedule of stock award	For the nine months ended September 30, 2018 For the year ended December 31, 2017 Number of shares vested in period 10,000 290,000 Fair market value per share $ 2.80 $ 2.80 Stock based compensation recognized $ 28,000 $ 812,000
Schedule of fair value options assumptions	Measurement date Dividend yield 0% Expected volatility 114.69 ~ 126.34% Risk-free interest rate 1.79% ~ 2.68% Expected life (years) 3 ~ 5 Stock Price $ 2.00 ~ 2.80 Exercise Price $ 0.40 ~ 2.00
Schedule of stock options	September 30, 2018 December 31, 2017 Weighted Average Weighted Average Shares Exercise Price Shares Exercise Price Outstanding, beginning of period 670,000 $ 1.93 - $ - Granted 50,000 $ 2.00 670,000 $ 1.93 Exercised - $ - - $ - Canceled - $ - - $ - Outstanding, end of period 720,000 $ 1.93 670,000 $ 1.93 Options exercisable, end of period 30,000 $ 2.00 13,334 $ 2.00 Options expected to vest, end of period 690,000 $ 1.93 656,666 $ 1.89 Weighted average fair value of options granted $ 2.30 $ 2.36

Capital Stock (Tables)

Capital Stock (Tables)	9 Months Ended
	Sep. 30, 2018
Capital Stock [Abstract]
Schedule of fair value warrants assumptions	Measurement date Dividend yield 0% Expected volatility 97.90~119.33% Risk-free interest rate 1.47~1.60% Expected life (years) 2.71~2.92 Stock Price $ 0.25 Exercise Price $ 0.40
Schedule of common stock purchase warrants were outstanding	Warrants (1) Weighted Average Exercise Price Outstanding – December 31, 2016 502,000 $ 0.40 Granted 64,000 0.40 Forfeited/Canceled - - Exercised 512,000 (2) 0.40 Outstanding – December 31, 2017 54,000 0.40 Granted - - Forfeited/Canceled - - Exercised 2,000 (3) 0.40 Outstanding – September 30, 2018 52,000 $ 0.40 (1) Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40. (2) During the year ended December 31, 2017, investors exercised 512,000 share purchase warrants and received 442,960 underlying shares for exercise on a cashless basis. (3) During the nine-month period ended September 30, 2018, investors exercised 2,000 share purchase warrants and received 1,715 underlying shares for exercise on a cashless basis.

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Level 1 [Member]
Liabilities
Derivative liabilities
Level 2 [Member]
Liabilities
Derivative liabilities
Level 3 [Member]
Liabilities
Derivative liabilities	$ 30,506	$ 31,090

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details 1) - shares	9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	1,476,284	598,878
Stock options vested [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	30,000
Stock options not yet vested [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	690,000
Stock awards not yet vested [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	290,000
Series A Preferred shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	700	700
Stock purchase warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	52,000	566,000
Research Warrants at 3% of issued and outstanding shares [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	384,806
Convertible Notes [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Potentially dilutive securities net loss per share	28,778	32,178

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Summary of Significant Accounting Policies (Textual)
Research and development costs	$ 104,798	$ 8,406	$ 237,770	$ 10,120
Advertising or marketing costs			$ 48,832	$ 15,657
Research warrants issued and outstanding, percentage			3.00%

Convertible Note - Related Pa_3

Convertible Note - Related Party and Derivative Liabilities (Details) - USD ($)	Sep. 30, 2018	Dec. 31, 2017
Convertible Note - Related Party and Derivative Liabilities [Abstract]
Face value of certain convertible notes	$ 25,000	$ 25,000
Less: unamortized discount		(18,335)
Carrying value	$ 25,000	$ 6,665

Convertible Note - Related Pa_4

Convertible Note - Related Party and Derivative Liabilities (Details 1)	9 Months Ended
	Sep. 30, 2018USD ($)
Convertible Note - Related Party and Derivative Liabilities [Abstract]
Balance at December 31, 2017	$ 31,090
Derivative addition associated with convertible notes
Change in fair value	(584)
Balance at September 30, 2018	$ 30,506

Convertible Note - Related Pa_5

Convertible Note - Related Party and Derivative Liabilities (Details 2)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Derivative [Line Items]
Expected dividends	0.00%	0.00%
Risk free interest rate	2.59%
Commitment Date [Member]
Derivative [Line Items]
Expected dividends	0.00%
Risk free interest rate	1.33%
Minimum [Member]
Derivative [Line Items]
Expected volatility	77.00%	110.00%
Expected term	11 months 1 day	8 months 2 days
Risk free interest rate		1.53%
Minimum [Member] | Commitment Date [Member]
Derivative [Line Items]
Expected volatility	101.00%
Expected term	11 months 1 day
Maximum [Member]
Derivative [Line Items]
Expected volatility	83.00%	115.00%
Expected term	11 months 26 days	8 months 26 days
Risk free interest rate		1.65%
Maximum [Member] | Commitment Date [Member]
Derivative [Line Items]
Expected volatility	103.00%
Expected term	1 year

Convertible Note - Related Pa_6

Convertible Note - Related Party and Derivative Liabilities (Details Textual) - USD ($)	Sep. 09, 2018	Sep. 28, 2017	Sep. 27, 2017	Sep. 01, 2016	Jun. 30, 2018	Jun. 30, 2017	Sep. 30, 2018	Sep. 30, 2017
Convertible Note - Related Party and Derivative Liabilities (Textual)
Received proceeds totaling								$ 15,000
Amortization of discount					$ 5,541	$ 1,571	$ 18,335	$ 6,599
CubeSquare, LLC [Member]
Convertible Note - Related Party and Derivative Liabilities (Textual)
Received proceeds totaling			$ 15,000	$ 10,000
Interest rate per annum			8.00%	8.00%
Conversion, description			Any portion of the principal and unpaid interest under the note is convertible at any time at the option of CubeSquare into shares of common stock of the Company at a conversion price equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from CubeSquare.	(i) $0.0625 per share if the Company's shares are not trading on a public market and; (ii) in the event the Company's shares are listed for trading on a public market, the conversion price shall be equal to a 50% discount to the average of the five lowest trading prices during the previous twenty trading days prior to the date of the notice of conversion from the lender.
Maturity date				Sep. 1, 2017
Maturity date, description	Note 2 was amended to extend the maturity date until September 27, 2019.	Note 1 to extend the maturity date from September 1, 2017 to September 1, 2018 and on September 9, 2018, the Company further amended Note 1 to extend the maturity date to September 1, 2019, under the same terms and conditions.
Debt instument due date			Sep. 27, 2018
CubeSquare, LLC [Member] | President [Member]
Convertible Note - Related Party and Derivative Liabilities (Textual)
Ownership percentage				25.00%

License and Research Funding _2

License and Research Funding Agreements (Details) - USD ($)	Mar. 06, 2018	Dec. 13, 2017	Dec. 14, 2016	Apr. 23, 2018	Sep. 30, 2018	Sep. 30, 2017	Sep. 30, 2018	Sep. 30, 2017	Dec. 31, 2017
License and Research Funding Agreements (Textual)
Research and development costs					$ 104,798	$ 8,406	$ 237,770	$ 10,120
Shares issued for advisory services, value				75,000
License and research funding agreement compensation paid, description	The Company entered into an additional service agreement with Ariel for the services of Professor Gadi Turgeman and his stem cells research team in their lab pursuant to which the Company paid Ariel $20,580 on each of March 19, 2018 and August 22, 2018.						The Company paid Ariel (i) $17,250 on December 19, 2017 and an additional $17,250 on April 26, 2018. On April 12, 2018, the Services Agreement was amended to provide for the payment by the Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request.
Ariel University [Member]
License and Research Funding Agreements (Textual)
Shares issued for advisory services, value		119,950
Shares issued, value		$ 335,860
Shares issued, percentage		1.00%
License Agreement [Member]
License and Research Funding Agreements (Textual)
Total amount of fund for research during research period			$ 100,000
Warrant exercisable percentage			4.00%
Payments of completion of milestone events, description			Upon successful clinical FDA Phase II completion - $130,000; and Upon successful clinical FDA Phase III completion - $390,000
Research and development costs									$ 1,179,777
Aforementioned funding amount									119,950
Stock based compensation									812,000
Payments of completion of milestone events due			6 months
Shares issued, value									$ 335,860

Commitments (Details)

Commitments (Details) - USD ($)

Oct. 08, 2018

Jul. 12, 2018

Jun. 23, 2018

Apr. 12, 2018

Apr. 23, 2018

Jan. 23, 2018

Nov. 15, 2017

Sep. 30, 2018

Dec. 31, 2017

Aug. 22, 2018

Aug. 15, 2018

May 01, 2018

Apr. 26, 2018

Apr. 16, 2018

Mar. 19, 2018

Dec. 14, 2017

Commitments (Textual)

Compensation for the services provided

$ 17,250

$ 17,250

$ 17,250

Compensation cost

$ 1,438

Service agreement payment, description

The Company of an additional monthly fee, commencing March 2018, of up to 8,000 Israeli shekels as compensation for additional costs which the Company may request.

Consulting fee

$ 5,000

Investor relations agreement, description

The Company gave notice of rescission of the agreement to such firm and requested the return of the consulting fee paid and the 75,000 shares of common stock. As a result, the Company has not recorded any fees for services rendered past June 23, 2018. A total of $10,000 representing April 2018 and May 2018 monthly consulting fees is reflected in the statement of operations and a total of $150,000, the fair market value of the issued shares, was expensed on issue.

The Company issued 75,000 shares of its common stock in respect of an investor relations services agreement which was rescinded on June 23, 2018 (Note 6(5)). The shares were valued at the fair market value on the date of issuance for a total of $150,000, or $2.00 per share.

Paid for additional fees

$ 14,082

Issuance of common stock payable

75,000

Service Agreement with Ariel [Member]

Commitments (Textual)

Compensation for the services provided

$ 20,580

$ 20,580

$ 17,250

Compensation cost

25,875

Prepaid expenses

41,160

Prepaid expensed during period

24,010

Outstanding expenses

17,150

Sponsored Research Agreement [Member]

Commitments (Textual)

Prepaid expenses

36,293

Prepaid expensed during period

9,073

Outstanding expenses

$ 27,220

Sponsored research agreement, description

The Company entered into a one-year sponsored research agreement (the "Sponsored Research Agreement"), with the Trustees of Dartmouth College ("Dartmouth") pursuant to which the Company will support and fund the cost of research conducted by Dartmouth of mutual interest to the parties in accordance with the Agreement. Intellectual property invented or developed solely by a party shall be owned by such party and intellectual property jointly invented or developed shall be jointly owned. Dartmouth shall retain an irrevocable worldwide right to use intellectual property owned by it resulting from its research under the Agreement on a non-exclusive royalty-free basis for research and education purposes. The Company funded $36,293 on August 20, 2018 and will fund additional $18,147 by December 1, 2018 and $18,146 by June 1, 2019, respectively.

2016 Stock Option and Award Plan [Member]

Commitments (Textual)

Advisors are granted the option

10,000

20,000

Stock option and advisor granted

30,000

20,000

30,000

Subsequent Event [Member] | Service Agreement with Ariel [Member]

Commitments (Textual)

Compensation cost

$ 7,187

Stock Plan (Details)

Stock Plan (Details) - USD ($)	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Stock Plan [Abstract]
Number of shares vested in period	10,000	290,000
Fair market value per share	$ 2.80	$ 2.80
Stock based compensation recognized	$ 28,000	$ 812,000

Stock Plan (Details 1)

Stock Plan (Details 1) - Stock Options [Member] - Measurement Date [Member]	9 Months Ended
	Sep. 30, 2018$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Exercise Price, Minimum	$ 0.40
Exercise Price, Maximum	$ 2
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	114.69%
Risk-free interest rate	1.79%
Expected life (years)	3 years
Stock Price	$ 2
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	126.34%
Risk-free interest rate	2.68%
Expected life (years)	5 years
Stock Price	$ 2.80

Stock Plan (Details 2)

Stock Plan (Details 2) - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2018	Dec. 31, 2017
Stock Plan [Abstract]
Shares Outstanding, beginning of period	670,000
Shares, Granted	50,000	670,000
Shares, Exercised
Shares, Canceled
Shares Outstanding, end of period	720,000	670,000
Shares Options exercisable, end of period	30,000	13,334
Shares, Options expected to vest, end of period	690,000	656,666
Weighted Average Shares Exercise Price, Outstanding, beginning of period	$ 1.93
Weighted Average Shares Exercise Price, Granted	2	1.93
Weighted Average Shares Exercise Price, Exercised
Weighted Average Exercise Price, Canceled
Weighted Average Shares Exercise Price, Outstanding, end of period	1.93	1.93
Weighted Average Exercise Price, Options exercisable, end of period	2	2
Weighted Average Exercise Price, Options expected to vest, end of period	1.93	1.89
Weighted Average Exercise Price, Weighted average fair value of options granted	$ 2.30	$ 2.36

Stock Plan (Details Textual)

Stock Plan (Details Textual) - USD ($)	Aug. 15, 2018	Dec. 14, 2017	Dec. 04, 2017	Dec. 14, 2016	Apr. 16, 2018	Nov. 15, 2017	Sep. 30, 2018	Sep. 30, 2018	Dec. 31, 2017	Jan. 23, 2018
Stock Plan (Textual)
Total unrecognized compensation remaining to be recognized in future periods								$ 92,671
General and administrative expenses [Member]
Stock Plan (Textual)
Stock-based compensation							$ 48,078	122,816	$ 29,000
Stock Options granted to Officers [Member]
Stock Plan (Textual)
Total unrecognized compensation remaining to be recognized in future periods								246,755
Weighted average exercise price			$ 2
Shares of common stock under certain vesting terms			5 years
Vest and exercisable date			Dec. 4, 2018
Granted an option to purchase shares of common stock			300,000
Stock Options granted to Officers [Member] | General and administrative expenses [Member]
Stock Plan (Textual)
Stock-based compensation							$ 353,430	$ 1,060,290	$ 106,029
2016 Stock Option and Award Plan [Member]
Stock Plan (Textual)
Reserved shares for issuance				10,000,000
Stock award										10,000
Description of services agreement	Under the 2016 Stock Option and Award Plan, the Board granted a Science Advisor an option to purchase an aggregate of 20,000 shares of common stock at an exercise price of $2.00 per share. The option vests as to 6,667 shares on each of August 15, 2018 and August 15, 2019 and as to 6,666 shares on August 15, 2020 and remains exercisable as to each such installment for three years from the date of vesting.				Under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 10,000 shares of common stock, exercisable on April 16, 2018 at an exercise price of $2.00 per share and (ii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2019 at an exercise price of $2.00 per share, and (iii) an option to purchase 10,000 shares of common stock exercisable on April 16, 2020 at an exercise price of $2.00 per share, provided the advisor is still providing services to the Company. provided the advisor is still providing services to the Company.	Under the 2016 Stock Option and Award Plan, the Board awarded two of its Science Advisors the following three-year stock options: (i) an immediately exercisable option to purchase 6,667 shares of common stock at an exercise price of $2.00 per share, (ii) an option to purchase 6,667 shares of common stock exercisable on November 15, 2018 at an exercise price of $2.00 per share and (iii) an option to purchase 6,666 shares of common stock exercisable on November 15, 2019 at an exercise price of $2.00 per share, provided the advisors are still providing services to the Company.
2016 Stock Option and Award Plan one [Member]
Stock Plan (Textual)
Description of services agreement						Under the 2016 Stock Option and Award Plan, the Board awarded a Science Advisor, the following three-year stock options: (i) an option to purchase 15,000 shares of common stock, exercisable on November 15, 2018 at an exercise price of $0.40 per share and (ii) an option to purchase 15,000 shares of common stock exercisable on November 15, 2019 at an exercise price of $0.40 per share, provided the advisor is still providing services to the Company.
Board of Directors Chairman [Member]
Stock Plan (Textual)
Stock award				440,000
Receive common stock vest upon grant date				150,000
Vested shares		145,000		145,000
Board of Directors Chairman [Member] | December 14, 2018 [Member]
Stock Plan (Textual)
Vested shares								145,000
Stock awards are expected to vest [Member] | Fourth Quarter [Member]
Stock Plan (Textual)
Vested shares								290,000

Capital Stock (Details)

Capital Stock (Details) - Measurement Date [Member] - Stock Purchase Warrants [Member]	9 Months Ended
	Sep. 30, 2018$ / shares
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Dividend yield	0.00%
Stock Price	$ 0.25
Exercise Price	$ 0.40
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	119.33%
Risk-free interest rate	1.60%
Expected life (years)	2 years 11 months 1 day
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected volatility	97.90%
Risk-free interest rate	1.47%
Expected life (years)	2 years 8 months 16 days

Capital Stock (Details 1)

Capital Stock (Details 1) - Stock Purchase Warrants [Member] - $ / shares		9 Months Ended		12 Months Ended
		Sep. 30, 2018		Dec. 31, 2017
Warrants
Outstanding - Beginning balance	[1]	54,000		502,000
Granted	[1]			64,000
Forfeited/Canceled	[1]
Exercised	[1]	2,000		512,000
Outstanding - Ending balance	[1]	52,000		54,000
Weighted Average Exercise Price
Outstanding - Beginning balance		$ 0.40		$ 0.40
Granted				0.40
Forfeited/Canceled
Exercised		0.40	[2]	0.40	[3]
Outstanding - Ending balance		$ 0.40		$ 0.40
[1]	Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40.
[2]	During the nine-month period ended September 30, 2018, investors exercised 2,000 share purchase warrants and received 1,715 underlying shares for exercise on a cashless basis.
[3]	During the year ended December 31, 2017, investors exercised 512,000 share purchase warrants and received 442,960 underlying shares for exercise on a cashless basis.

Capital Stock (Details Textual)

Capital Stock (Details Textual) - USD ($)		Jun. 23, 2018	Feb. 06, 2018	Dec. 14, 2017	Dec. 13, 2017	Sep. 16, 2018	Apr. 23, 2018	Jan. 23, 2018	Sep. 30, 2018	Dec. 31, 2017
Capital Stock (Textual)
Common stock, shares authorized									100,000,000	100,000,000
Common stock, par value									$ 0.0001	$ 0.0001
Series A Preferred Shares, shares issued									2,000	2,000
Series A Preferred Shares, shares outstanding									2,000	2,000
Series A Preferred Shares, authorized									10,000	10,000
Series A Preferred Shares, par value									$ 0.001	$ 0.001
Shares issued for advisory services, value							75,000
Subscriptions shares										128,000
Warrant, description			The Company received a warrant exercise notice in respect of 2,000 warrants from a subscriber and issued 1,715 shares of common stock on a cashless exercise basis as per the cashless exercise formula contained in the warrant.
Warrants received underlying shares for exercise on a cashless basis										442,960
Investor relations agreement, description		The Company gave notice of rescission of the agreement to such firm and requested the return of the consulting fee paid and the 75,000 shares of common stock. As a result, the Company has not recorded any fees for services rendered past June 23, 2018. A total of $10,000 representing April 2018 and May 2018 monthly consulting fees is reflected in the statement of operations and a total of $150,000, the fair market value of the issued shares, was expensed on issue.					The Company issued 75,000 shares of its common stock in respect of an investor relations services agreement which was rescinded on June 23, 2018 (Note 6(5)). The shares were valued at the fair market value on the date of issuance for a total of $150,000, or $2.00 per share.
Additional share of common stock per share									$ 0.40
License Agreement Terms [Member]
Capital Stock (Textual)
Share issued for agreement					119,950
Conversion value					$ 335,860
Conversion of stock par value					$ 2.80
Investors [Member]
Capital Stock (Textual)
Warrant exercise									2,000
Warrants received underlying shares for exercise on a cashless basis									1,715
Scientific Advisors [Member]
Capital Stock (Textual)
Share issued for agreement				290,000
Conversion value				$ 812,000
Conversion of stock par value				$ 2.80
Private Placement [Member]
Capital Stock (Textual)
Sale and issuance of common stock						22,728		312,500
Total proceeds of subscriptions amount						$ 25,000		$ 500,000		$ 32,000
Investor relations agreement, description								The Company issued 10,000 shares for advisory services (Note 6(4)). The shares were valued at fair market value on the date of issuance for a total of $28,000 or $2.80 per share.
Warrant [Member]
Capital Stock (Textual)
Warrant exercise	[1]								2,000	512,000
Series A Preferred Stock [Member]
Capital Stock (Textual)
Preferred stock, conversion basis, description									The Series A Preferred Stock is redeemable at the option of the Company at any time, in whole or in part, upon 10 trading days prior notice, at a price of $1.00 per share plus 4% per annum from the date of issuance (the "Stated Value"). The holders of the Series A Preferred Stock are entitled to a liquidation preference equal to the Stated Value, prior to the holders of other preferred stock or common stock. The holders of the Series A Preferred Stock have the right to convert such stock into common stock at a conversion rate equal to the Stated Value as of the conversion date divided by the average closing price of the common stock for the five previous trading days. The Company is required to reserve sufficient number of shares for the conversion of the Series A Preferred Stock. The holders of Class A Preferred Stock shall vote together as a single class with the holders of the Company's common stock and the holders of any other class or series of shares entitled to vote with the common stock, with the holders of Class A Preferred Stock being entitled to 66 2/3% of the total votes on all such matters, regardless of the actual number of shares of Class A Preferred Stock then outstanding.
[1]	Each two shares of common stock purchased under the private placement provides for one warrant to acquire an additional share of common stock together with the payment of $0.40.

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event [Member]	Oct. 08, 2018USD ($)shares
Subsequent Events (Textual)
Sale and issuance of common stock | shares	22,728
Total proceeds of subscriptions amount | $	$ 25,000